Baxter/$BAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Baxter
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Ticker
$BAX
Sector
Primary listing
NYSE
Employees
38,000
Headquarters
Website
Baxter Metrics
BasicAdvanced
$12B
-
-$0.31
0.58
$0.68
2.99%
Price and volume
Market cap
$12B
Beta
0.58
52-week high
$37.74
52-week low
$21.33
Average daily volume
5.9M
Dividend rate
$0.68
Financial strength
Current ratio
2.296
Quick ratio
1.209
Long term debt to equity
133.237
Total debt to equity
146.144
Interest coverage (TTM)
2.93%
Profitability
EBITDA (TTM)
2,039
Gross margin (TTM)
38.93%
Net profit margin (TTM)
-1.42%
Operating margin (TTM)
9.52%
Effective tax rate (TTM)
25.16%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
2.73%
Return on equity (TTM)
-3.21%
Valuation
Price to revenue (TTM)
1.069
Price to book
1.65
Price to tangible book (TTM)
-3.5
Price to free cash flow (TTM)
53.379
Free cash flow yield (TTM)
1.87%
Free cash flow per share (TTM)
0.426
Dividend yield (TTM)
2.99%
Forward dividend yield
2.99%
Growth
Revenue change (TTM)
-27.24%
Earnings per share change (TTM)
-106.44%
3-year revenue growth (CAGR)
-7.80%
10-year revenue growth (CAGR)
0.48%
3-year earnings per share growth (CAGR)
-46.50%
10-year earnings per share growth (CAGR)
-22.66%
3-year dividend per share growth (CAGR)
-10.87%
10-year dividend per share growth (CAGR)
-9.11%
What the Analysts think about Baxter
Analyst ratings (Buy, Hold, Sell) for Baxter stock.
Bulls say / Bears say
Baxter lowered its 2025 adjusted EPS guidance to $2.42–$2.52, below analysts’ forecast of $2.52, after posting Q2 adjusted EPS of $0.59, missing the $0.61 consensus, as ongoing disruptions from Hurricane Helene affected its IV solutions output (Reuters)
The pharmaceuticals division lagged in Q2 2025: injectable drug sales slipped 1% and anesthesia revenue dropped by a low double-digit percentage worldwide, underscoring continued weakness in the company’s core pharma portfolio (Reuters)
Baxter voluntarily halted shipments of its Novum IQ Large Volume Pump following safety incidents, including two reported deaths, raising regulatory scrutiny and reputational concerns (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Baxter Financial Performance
Revenues and expenses
Baxter Earnings Performance
Company profitability
Baxter News
AllArticlesVideos
BAX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Business Wire23 hours ago
Baxter International Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – BAX
Business Wire2 days ago
Rosen Law Firm Urges Baxter International Inc. (NYSE: BAX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Business Wire5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Baxter stock?
Baxter (BAX) has a market cap of $12B as of October 22, 2025.
What is the P/E ratio for Baxter stock?
The price to earnings (P/E) ratio for Baxter (BAX) stock is 0 as of October 22, 2025.
Does Baxter stock pay dividends?
Yes, the Baxter (BAX) stock pays dividends to shareholders. As of October 22, 2025, the dividend rate is $0.68 and the yield is 2.99%. Baxter has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Baxter dividend payment date?
The next Baxter (BAX) dividend payment date is unconfirmed.
What is the beta indicator for Baxter?
Baxter (BAX) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.